Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Amgen Inc. | Olpasiran (AMG 890) - (OCEAN(a)-DOSE) | Cardiovascular disease / Elevated Lipoprotein | Phase 3 | Trial Planned | Subcutaneous | Cardiology |
| Amgen Inc. | KHK4083/AMG 451 - (ROCKET) | Atopic dermatitis | Phase 3 | Intravenous | Immunology | |
| Amgen Inc. | Daxdilimab (HZN-7734) | Dermatomyositis | Phase 2 | Intravenous | Immunology | |
| Amgen Inc. | OTEZLA | Palmoplantar pustulosis for Japanese patients | Phase 2 | oral | Immunology | |
| Amgen Inc. | Otezla (apremilast) - (DISCREET) | Moderate to severe genital psoriasis | Phase 3 | oral | #N/A | |
| Amgen Inc. | BLINCYTO | Acute lymphoblastic leukemia (ALL) - pediatric | Phase 3 | Intravenous | Oncology | |
| Amgen Inc. | Tezepelumab | Eosinophilic esophagitis (EoE) | Phase 3 | Ongoing | Subcutaneous | Gastroenterology |
| Amgen Inc. | Dazodalibep (HZN-4920) | Focal segmental glomerulosclerosis | Phase 2 | Subcutaneous | #N/A |
